🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

James E. Thompson

Roswell Park Comprehensive Cancer Center

ORCID: 0000-0003-3030-7559

Also affiliated with University of Strathclyde

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Prediction of Life-threatening and Disabling Bleeding in Patients with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy”.

Prediction of Life-threatening and Disabling Bleeding in Patients with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

medRxiv(2021)10.1101/2021.09.24.21263986
N/A
0DataRank · unranked
0 citations

Manu Pandey, Yael Flamand, J. Erika Haydu, Roger Belizaire, Rahul S. Vedula +15 more

Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy

Blood Advances(2022)10.1182/bloodadvances.2021006166
N/A
0DataRank · unranked
25 citations

Manu Pandey, Yael Flamand, J. Erika Haydu, Roger Belizaire, Mark G. Faber +16 more

A phase II study of CPX-351 in younger patients < 60 years old with secondary acute myeloid leukemia: Trial in progress.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps7073
N/A
0DataRank · unranked
0 citations

Salman Fazal, Elizabeth A. Griffiths, James E. Thompson, Pamela J. Sung, Steven Daniel Green +8 more

Gemtuzumab ozogamicin plus standard induction chemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia

Blood Cancer Journal(2023)10.1038/s41408-023-00910-x
N/A
0DataRank · unranked
8 citations

Mina Abdelmalek, Tara Cronin, Jeffrey Baron, Zakariya Kashour, Farhan Azad +10 more